imipramine for the treatment of cocaine and methamphetamine dependence.

NLM AIDSLINE Imipramine for the treatment of cocaine and methamphetamine dependence. Galloway GP; Newmeyer J; Knapp T; Stalcup SA; Smith D; Drug
August 30, 1995

J Addict Dis. 1994;13(4):201-16. Unique Identifier : AIDSLINE At the Drug Detoxification, Rehabilitation, and Aftercare Program of the Haight-Ashbury Free Clinics, we conducted a double-blind, controlled, randomized clinical trial of imipramine in the treatment of cocaine and methamphetamine abusers. The purpose of the trial was to test the efficacy of imipramine as a treatment for stimulant dependence and to establish the feasibility of conducting a controlled clinical trial at the clinic under conditions that approximated usual clinical practice. Subjects were randomly assigned to receive either 10 or 150 mg/day of imipramine. Imipramine 10 mg/day was the control condition. Subjects could receive study medication for up to 180 days. One-hundred eighty-three subjects participated in the study: 151 were cocaine dependent and 32 were methamphetamine dependent. In addition to receiving study medication, all subjects were assigned to intensive drug abuse counseling, which included an HIV education component. Using an intention-to-treat analysis, we found that retention in treatment was significantly longer for subjects who were treated with 150 mg of imipramine compared to control. However, we found no consistent differences between the two groups of subjects in Beck Depression Inventory scores, stimulant craving, self-report of time since last use of stimulants, or percent of urinalyses positive for stimulants. The feasibility of conducting a controlled, randomized clinical trial of medication for treatment of drug abuse was established for this community clinic setting. Cocaine Combined Modality Therapy Comparative Study Counseling Dose-Response Relationship, Drug Double-Blind Method Feasibility Studies Female Follow-Up Studies Human Imipramine/THERAPEUTIC USE Male Methamphetamine Patient Dropouts/PSYCHOLOGY Substance Dependence/PSYCHOLOGY/REHABILITATION Substance Withdrawal Syndrome/DIAGNOSIS/PSYCHOLOGY Support, U.S. Gov't, P.H.S. Treatment Outcome CLINICAL TRIAL JOURNAL ARTICLE RANDOMIZED CONTROLLED TRIAL

Most Read: Latest Added Related Topics White House LGBT Conference on HIV/AIDS UNITED STATES: White House in Atlanta: LGBT AIDS Conference No more single-theme conferences: global HIV prevention conference planned FHI 360 Senior Scientist Lut Van Damme Receives International Microbicide Conference Lifetime Achievement Award Equatorial Guinea Ministry of Health and Social Welfare and UNICEF Refute Erroneous AIDS Prevalence Figures Photographs from A Day with HIV Now Online Bulgaria urges Libya to investigate AIDS nurses case Engineers enter fight against AIDS in Africa Gilead’s Complera® Non-Inferior to Atripla® Among Treatment-Naive HIV Patients UN chief Ban calls world leaders to end Aids by 2020 UNAIDS and Lancet to bring together political and health leaders to shape the debate on the future of global health New Hampshire nears approval of medical marijuana law Celebrating 10 years of PEPFAR Afrique: naissance du millionième bébé indemne du sida après 10 ans d'un plan américain New Analysis of World's Premier AIDS Conference Finds Poor Coverage of Populations Most-at-Risk for HIV INDIANA: HepFest Provides Hepatitis C Awareness PENNSYLVANIA: Nutrition Organization 'Manna' Celebrates Delivery of Its 10,000,000th Meal GREECE: Doubled HIV Cases Add to Greek Woes OHIO: Phila Health Department HIV Testing Well-Received CONNECTICUT: City's Circle Care Center is a Model for HIV Prevention CLAAD Urges FDA To End Abstinence-Only Stance On Addiction Treatment Exploring the risks of liver cancer after successful treatment for hepatitis C virus Thousands still missing HIV treatment following CAR coup European Commission Approves Stribild®, a New Single Tablet Regimen for the Treatment of HIV-1 Infection European Commission Approves Stribild®, a New Single Tablet Regimen for the Treatment of HIV-1 Infection CHINA: Hepatitis B Treatment to Improve NIH Scientists Discover How HIV Kills Immune Cells: Findings Have Implications for HIV Treatment Immunotherapy Offers New Options for Cancer Treatment AZT associated with poorer immunological recovery in people taking first-line HIV treatment in southern Africa ILLINOIS: Task Force Will Heighten Public Awareness about Screening and Treatment for Hepatitis Virus
Information in this article was accurate in August 30, 1995. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.